Reduce the intensity of debilitating symptoms such as anxiety, depression, poor concentration, insomnia, restlessness, nightmares, panic states, exaggerated startle response, and phobias.
Improve the patient’s mental state and attention focus to be more amenable and ready to benefit from psychotherapeutic interventions.
Provide the benefit of psychopharmalogical interventions in patients who have the comorbidity of a dissociative disorder with another psychiatric disorder such as major depression, bipolar disorder, panic disorder, obsessive-compulsive disorder, and so forth.
KeywordsObstructive Sleep Apnea Sleep Apnea Psychotropic Medication Panic Disorder Posttraumatic Stress Disorder
Unable to display preview. Download preview PDF.
- Amrein, R., Allen, S. R., Guentert, T. W, Hartmann, D., Lorscheid, T, Schoerlin, M. P, & Vranesic, D. (1989). Pharmacology of reversible MAOI. British Journal of Psychiatry, 144, 66–71.Google Scholar
- Barkin, R., Braun, B. G., & Kluft, R. P. (1986). The dilemma of drug therapy for multiple personality disorder. In B. G. Braun (Ed.), The treatment of multiple personality disorder (pp. 107–132 ). Washington, DC: American Psychiatric Press.Google Scholar
- Braun, B. G. (Ed.) (1986). The treatment of multiple personality disorder. Washington, DC: American Psychiatric Press.Google Scholar
- Braun, B. G. (1990a). Unusual medication regimens in the treatment of dissociative disorder patients: Part I. Noradrenergic agents. Dissociation, 3, 144–150.Google Scholar
- Braun, B. G. (1990b). The use of naltrexone in the treatment of dissociative disorder patients. In B. G. Braun (Ed.), Seventh International Conference on Multiple Personality and Dissociative States (p. 20 ). Rush University Department of Psychiatry, Chicago, IL.Google Scholar
- Chu, J. (1995). Successful use if Risperidone (Risperdal) in the treatment of DID patients. Personal communication.Google Scholar
- Evans, E. J. (1985). Expectancy, therapeutic instructions, and the placebo response. In L. White, B. Tursky, and G. E. Schwartz (Eds.), Placebo: Theory, research and mechanisms (pp. 215–228 ). New York: Guilford.Google Scholar
- Friedman, M. J. (1994). Biological and pharmacological aspects of the treatment of PTSD. In M. B. Williams and J. F. Sommor (Eds.), Handbook of posttraumatic therapy (pp. 495–509 ). Westport, CT: Greenwood.Google Scholar
- Gainer, M. J. & Torem, M. S. (1994). Clinical corner: Sleep and dissociation-New findings. ISSD Newsletter, 12 (4), 8.Google Scholar
- Kluft, R. P. (1984). Aspects of the treatment of multiple personality disorder. Psychiatric Annals, 14, 51–55.Google Scholar
- Kluft, R. P. (1985). The treatment of multiple personality disorder (MPD). Current concepts. In E F. Flach (Ed.), Directions in psychiatry (pp. 1–10 ). New York, Hatherleigh.Google Scholar
- Larson, J. K., Gjerris, A., Holm, P, Anderson, J., Bille, A., Christensen, E. M., Hoyer, E., Jensen, H., Mejlhede, A., & Langagergaard, A. (1991). Moclobemide in depression: A randomized, multicentre trial against isocarboxazide and clomipramine emphasizing atypical depression. Acta Psychiatrica Scandinavica, 84 (6), 564–570.CrossRefGoogle Scholar
- Loewenstein, R. J., Hornstein, N., Barber, B. (1988). Open trial of clonazepam in the treatment of posttraumatic stress symptoms in MPD. Dissociation, 1, 3–12.Google Scholar
- Montgomery, S. (1993). Venlafaxine: a new dimension in antidepressant pharmacotherapy. Journal of Clinical Psychiatry, 54 (3), 119–126.Google Scholar
- Putnam, F. W. (1986). The treatment of multiple personality: State of the art. In B. G. Braun (Ed.), Treatment of multiple personality disorder (pp. 175–198 ). Washington, DC: American Psychiatric Press.Google Scholar
- Putnam, E. W. (1989). Diagnosis and treatment of multiple personality disorder. New York: Guilford. Ross, C. A. (1989). Multiple personality disorder Diagnosis, clinical features, and treatment. New York: Wiley.Google Scholar
- Rossel, L. & Moll, E. (1990). Moclobemide versus tranylcypromine in the treatment of depressions. Acta Psychiatrica Scandinavica, Supplementum, 360, 61–62.Google Scholar
- Shapiro, A. K. & Morris, L. A. (1978). The placebo effect in medical and psychological therapies. In S. L.Google Scholar
- Garfield & A. E. Bergin, (Eds.), Handbook of psychotherapy and behavior change (2nd ed., pp.Google Scholar
- 369-.). New York: Wiley.Google Scholar
- Spiegel, D. (1986). Dissociation, double binds, and posttraumatic stress. In B. G. Braun (Ed.), The treatment of multiple personality disorder (pp. 61–77 ). Washington DC: American Psychiatric Press.Google Scholar
- Torem, M. S., & Gainer, M. J. (1993). Treatment of MPD: A systems approach. Paper presented at the Eighth Regional Conference on Trauma, Dissociation, and Multiple Personality, April 23–24, Akron, OH.Google Scholar
- Torem, M. S., & Gainer, M. J. (1995). The center core: Imagery for experiencing the unifying self. Hypnos, 22, 125–131.Google Scholar
- van der Kolk, B. A. (1987). The drug treatment of post-traumatic stress disorder. Journal of Affective Disorders, 13, 203–213.Google Scholar
- Wolin, R. E. (1994). Successful use of risperidone (Risperdal) in the treatment of patients with dissociative disorders. Personal communication.Google Scholar